XML 15 R5.htm IDEA: XBRL DOCUMENT v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ (DEFICIT) EQUITY - USD ($)
Total
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Beginning balance (in shares) at Dec. 29, 2024   117,116,311    
Beginning balance at Dec. 29, 2024 $ 446,145,000 $ 117,000 $ 1,321,386,000 $ (875,358,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net income (loss) $ (25,039,000)     (25,039,000)
Exercise of stock options (in shares) 210,708 210,708    
Exercise of stock options $ 1,683,000 $ 1,000 1,682,000  
Issuance of common stock related to restricted shares (in shares)   341,116    
Shares repurchased for employee tax withholding (in shares) (9,651)      
Shares repurchased for employee tax withholding $ (256,000)      
Stock-based compensation expense 10,221,000   10,221,000  
Ending balance (in shares) at Mar. 30, 2025   117,658,484    
Ending balance at Mar. 30, 2025 432,754,000 $ 118,000 1,333,033,000 (900,397,000)
Beginning balance (in shares) at Dec. 28, 2025   118,448,417    
Beginning balance at Dec. 28, 2025 356,125,000 $ 118,000 1,365,430,000 (1,009,423,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net income (loss) $ 125,809,000     125,809,000
Exercise of stock options (in shares) 1,000 1,000    
Exercise of stock options $ 8,000   7,000  
Issuance of common stock related to Spyce milestone achievement (in shares)   242,722    
Issuance of common stock related to Spyce milestone achievement 1,604,000   1,604,000  
Issuance of common stock related to restricted shares (in shares)   124,842    
Shares repurchased for employee tax withholding (in shares)   (238)    
Shares repurchased for employee tax withholding (419,000)   (419,000)  
Stock-based compensation expense 5,804,000   5,804,000  
Ending balance (in shares) at Mar. 29, 2026   118,816,743    
Ending balance at Mar. 29, 2026 $ 488,931,000 $ 119,000 $ 1,372,426,000 $ (883,614,000)